Meta analysis on cinepazide maleate in treatment of diabetic peripheral neuropath
-
摘要: 目的 对马来酸桂哌齐特治疗糖尿病周围神经病变(DPN)的疗效和安全性进行系统评价。 方法 检索Medline(1977~2011.11)、CNKI(1994~2011.11)、万方(1989~2011.11)、VIP(1989~2011.11)等数据库,收集有关马来酸桂哌齐特治疗糖尿病周围神经病变的随机临床对照试验研究(RCT)。通过文献质量评价,对纳入文献进行Meta分析。 结果 有11个试验982例患者纳入分析,纳入研究的文献经质量评价,均为C级。Meta分析显示:1有效率:马来酸桂哌齐特明显高于对照组,合并效应量OR及95%CI为5.91[3.71,9.43](P< 0.000 01)2神经功能改善:腓神经SNCV合并效应值WMD=2.52,95%CI(1.92,3.13);腓神经MNCV合并效应值WMD=3.07,95%CI(1.59,4.55);正中神经MNCV合并效应值WMD=3.97,95%CI(1.87,6.07);正中神经SNCV合并效应值WMD=2.94,95%CI(1.43,4.46);以上效应值均明显高于对照组;3不良反应:主要表现为轻度头痛、头晕、消化道不适。 结论 马来酸桂哌齐特治疗DPN可能有一定疗效,但由于尚缺乏高质量的RCT证据支持,马来酸桂哌齐特治疗DPN尚不能作出最后结论,还需进行更多高质量的 RCT才能得出肯定性结论。Abstract: Objective To assess the efficacy and safety of Cinepazide Maleate(CPZD) in the treatment of diabetic peripheral neuropath(DPN),with evidence-based medicine methods. Methods By retrieving related database,such as Medline(1977~2011.11), CNKI(1994~2011.11), WANFANG(1989~2011.11), VIP(1989~2011.11), the randomized controlled trials on DPN treatment by CPZD were included and analyzed according to the inclusion criteria.Meta analysis was used in this study. Results There were 982 cases of 11 trials were included in the analysis, the methodological quality of all studies included were rated as C-class. Meta-analysis showed that: 1Efficient: CPZD group was significantly higher than control group[OR and 95% CI=4.33 (2.45,7.66)]2Improvement of neurological function: The combined effect size of common peroneal nerve(CPN) SNCV and MNCV, median nerve(MN) SNCV and MNCV were as follows, CPN-SNCV:WMD=2.52,95%CI(1.92,3.13);CPN-MNCV:WMD=3.07,95%CI(1.59,4.55);MN-MNCV: WMD=3.97,95%CI(1.87,6.07);MN-SNCV:WMD=2.94,95%CI(1.43,4.46), the above-mentioned value were significantly higher than control group. 3Adverse reactions were less, mainly showed mild headache, dizziness, gastrointestinal discomfort. Conclusions Cinepazide Maleate might have positive effect on DPN. However,the evidence was not strong enough due to the general low methodological quality.A reliable conclusion about the effects of CPZD on DPN could not be summarized at the moment. Further large high-quality randomized controlled trials should be done.
-
[1] Kashyap AS,Anand KP, Kashyap S, et al. Peripheral neuropathy[J]. Lancet, 2004, 364(9446):1664. [2] 张 丽,黄道飞,刘 胜.心脑血管新药马来酸桂哌齐特药理及临床综述[J].中国临床医药研究杂志,2002, 7(6):7002. [3] 中华医学会糖尿病学分会.中国2型糖尿病防治指南(2007年版)[J].中华内分泌代谢杂志,2008,24(2):增录2a-3. [4] Laporte JR, CapellàD, Juan J. Agranulocytosis induced by cinepazide[J]. Eur J Clin Pharmacol, 1990, 38(4): 387. [5] 李 庆,叶 真,倪海祥.糖尿病周围神经病变的临床评估和诊断进展[J]. 浙江临床医学,2008,10(10):1388. [6] 陈国军,张燕柳,于永娜,等.马来酸桂哌齐特与甲钴胺联合治疗糖尿病周围神经病变观察[J].首都医药,2009,5(10):57. [7] 井爱芬,尹逊莲.马来酸桂哌齐特注射液治疗糖尿病周围血管神经病变70 例[J].中国民间疗法,2004,12(3):53. [8] 雷 涛,张秀珍.甲钴胺与马来酸桂哌齐特联合治疗糖尿病下肢神经病变的疗效观察[J].中国康复医学杂志,2006,21(6):552. [9] 李万甫,粟 爽.马来酸桂哌齐特注射液治疗糖尿病周围神经病变疗效观察[J].保健医学研究与实践,2007,4(1):36. [10] 李卫红.马来酸桂哌齐特联合甲钴胺治疗糖尿病周围神经病变的临床观察[J].中国药物与临床,2009,9(7):636. [11] 吕彩莲,王翠芬.银杏达莫注射液治疗糖尿病周围神经病变的疗效观察[J].实用医技杂志,2011,18(6):622. [12] 王红梅.马来酸桂哌齐特治疗糖尿病性神经病变的临床观察[J].临床和实验医学杂志,200,6(2):106. [13] 向 超.马来酸桂哌齐特联合甲钴胺治疗糖尿病周围神经病变100 例的疗效观察[J].中国现代药物应用,2011,5(4):116. [14] 张 敏,张翠云,肖 红,等.马来酸桂哌齐特对糖尿病周围神经病变的疗效评价[J].中国误诊学杂志,2011,11(27):6585. [15] 张秀坤,侯 英,徐明艳,等.马来酸桂哌齐特与B 族维生素联合治疗糖尿病周围神经病变疗效观察[J].黑龙江医学,2011,35(2):128. [16] 郑建勋.马来酸桂哌齐特治疗糖尿病周围神经病变疗效分析[J].中国社区医师:医学专业,2011,13(20):84. [17] 张晓霞,韩培云.马来酸桂哌齐特的药理作用及临床应用研究[J].中国药房, 2007, 18(26): 2060. [18] 白玉国,张爱琴,郑清敏,等.桂哌齐特注射液不良反应回顾性分析[J].药物流行病学杂志, 2008,17(3): 174. [19] 易湛苗,刘 芳,张 俊,等.桂哌齐特致血液系统不良反应的回顾与分析[J].药物不良反应杂志, 2010,12(4):251. -
点击查看大图
计量
- 文章访问数: 2745
- HTML全文浏览量: 247
- PDF下载量: 377
- 被引次数: 0
下载:
